Phase II trial of neoadjuvant camrelizumab and apatinib in resectable NSCLC: 3-year survival outcomes and dynamic circulating tumor DNA analysesW J Guo, Shugeng Gao, Fengwei Tan et al.|European Journal of Cancer|2025Cited by 2